CSIMarket
 


Mirum Pharmaceuticals Inc   (MIRM)
Other Ticker:  
 

Mirum Pharmaceuticals Inc 's Quick Ratio

MIRM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 4.1 below Mirum Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Quick Ratio than Mirum Pharmaceuticals Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the III Quarter 2023 to 153, from total ranking in the second quarter 2023 at 315.

Explain Quick Ratio?
How much Cash & cash equivalents MIRM´s has?
What are MIRM´s Current Liabilities?


MIRM Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 45.27 % 28.84 % 41.36 % 51.96 % 2.01 %
Y / Y Cash & cash equivalent Change 65.11 % 164.06 % -5.6 % -3.08 % -2.47 %
Quick Ratio MRQ 4.1 5.67 2.7 2.34 3.61
MIRM's Total Ranking # 153 # 315 # 1010 # 895 # 1001
Seq. Current Liabilities Change 28.28 % 19.16 % -24.54 % 25.94 % 13.78 %
Seq. Cash & cash equivalent Change -7.25 % 149.83 % -12.95 % -18.14 % 48.33 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 39
Healthcare Sector # 70
Overall Market # 153


Quick Ratio Statistics
High Average Low
12.56 6.39 2.34
(Dec 31 2020)   (Dec 31 2022)




Financial Statements
Mirum Pharmaceuticals Inc 's Current Liabilities $ 75 Millions Visit MIRM's Balance sheet
Mirum Pharmaceuticals Inc 's Cash & cash equivalent $ 306 Millions Visit MIRM's Balance sheet
Source of MIRM's Sales Visit MIRM's Sales by Geography


Cumulative Mirum Pharmaceuticals Inc 's Quick Ratio

MIRM's Quick Ratio for the trailling 12 Months

MIRM Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 45.27 % 28.84 % 41.36 % 51.96 % 2.01 %
Y / Y Cash & cash equivalent TTM Growth 65.11 % 164.06 % -5.6 % -3.08 % -2.47 %
Quick Ratio TTM 3.73 3.58 2.83 3.07 3.49
Total Ranking TTM # 628 # 718 # 937 # 1019 # 958
Seq. Current Liabilities TTM Growth 28.28 % 19.16 % -24.54 % 25.94 % 13.78 %
Seq. Cash & cash equivalent TTM Growth -7.25 % 149.83 % -12.95 % -18.14 % 48.33 %


On the trailing twelve months basis MIRM Cash & cash equivalent soared by 65.11 % in III Quarter 2023 year on year, faster than Current Liabilities, this led to increase in in Mirum Pharmaceuticals Inc 's Quick Ratio to 3.73, Quick Ratio remained below MIRM average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 486 other companies have achieved higher Quick Ratio than Mirum Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2128 to 3338.

Explain Quick Ratio?
How much Cash & cash equivalents MIRM´s has?
What are MIRM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 487
Healthcare Sector # 993
Within the Market # 153


trailing twelve months Quick Ratio Statistics
High Average Low
10.2 5.59 0.62
(Jun 30 2020)   (Jun 30 2019)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Artelo Biosciences Inc   11.10 $ 10.225  Millions$ 0.921  Millions
Erasca Inc   11.10 $ 296.668  Millions$ 26.730  Millions
Anaptysbio Inc   11.03 $ 413.047  Millions$ 37.437  Millions
Mei Pharma Inc   10.95 $ 82.202  Millions$ 7.509  Millions
Ocuphire Pharma Inc   10.84 $ 42.361  Millions$ 3.909  Millions
Atai Life Sciences N v   10.77 $ 208.994  Millions$ 19.403  Millions
Nkarta Inc   10.75 $ 275.613  Millions$ 25.640  Millions
Lipocine Inc   10.64 $ 23.848  Millions$ 2.241  Millions
Kinnate Biopharma Inc   10.62 $ 167.576  Millions$ 15.774  Millions
Caladrius Biosciences Inc   10.60 $ 54.394  Millions$ 5.132  Millions
Pasithea Therapeutics Corp   10.53 $ 19.680  Millions$ 1.869  Millions
Cryoport inc   10.41 $ 467.518  Millions$ 44.905  Millions
Structure Therapeutics Inc   10.22 $ 205.424  Millions$ 20.091  Millions
Actinium Pharmaceuticals Inc   10.18 $ 82.978  Millions$ 8.150  Millions
89bio Inc   9.99 $ 251.926  Millions$ 25.212  Millions
Lianbio  9.84 $ 252.222  Millions$ 25.627  Millions
Virios Therapeutics Inc   9.82 $ 4.786  Millions$ 0.487  Millions
Annexon Inc   9.63 $ 165.271  Millions$ 17.170  Millions
Syndax Pharmaceuticals Inc   9.54 $ 373.821  Millions$ 39.174  Millions
Milestone Pharmaceuticals inc   9.34 $ 75.746  Millions$ 8.114  Millions
Adicet Bio Inc   9.27 $ 183.257  Millions$ 19.768  Millions
Reneo Pharmaceuticals Inc   9.26 $ 125.614  Millions$ 13.563  Millions
Aerovate Therapeutics Inc   9.18 $ 135.199  Millions$ 14.725  Millions
Xenetic Biosciences Inc   9.15 $ 9.776  Millions$ 1.069  Millions
Werewolf Therapeutics Inc   9.01 $ 130.058  Millions$ 14.439  Millions
Igm Biosciences Inc   9.01 $ 386.991  Millions$ 42.965  Millions
Cytokinetics Incorporated  8.91 $ 539.239  Millions$ 60.487  Millions
Phathom Pharmaceuticals Inc   8.91 $ 213.677  Millions$ 23.979  Millions
Generation Bio Co   8.87 $ 291.025  Millions$ 32.819  Millions
Point Biopharma Global Inc   8.77 $ 339.163  Millions$ 38.666  Millions

Date modified: 2023-11-03T16:09:49+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com